CinCor Pharma is a biopharmaceutical company focused on developing its primary clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. CIN-107 is an oral small molecule inhibitor of aldosterone synthase, the enzyme responsible for the synthesis of aldosterone in the adrenal gland. CIN-107 inhibits aldosterone synthase activity, providing a differentiated mechanism for lowering aldosterone activity via a reduction of aldosterone synthesis, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Co. is developing CIN-107 for the indication of chronic kidney disease and primary aldosteronism. The CINC average annual return since 2022 is shown above.
The Average Annual Return on the CINC average annual return since 2022 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CINC average annual return since 2022 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CINC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|